Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody

information fournie par Boursorama •19/04/2016 à 08:00

Strasbourg, France, April 19, 2016 – Transgene SA (Euronext: TNG) today announced that pre-clinical data on an internally developed, new generation oncolytic viral immunotherapy product candidate was presented at the Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, USA.

Transgene is developing a new generation of oncolytic viral immunotherapies that are armed with cancer-fighting genes, seeking to provide enhanced efficacy to cancer patients while reducing toxicity. At the AACR meeting, Transgene reported pre-clinical results with three oncolytic vaccinia viruses, each containing a different form of a PD-1 blocker (VV-PD-1): a full monoclonal antibody (mAb), an antigen-binding fragment (Fab) or a single-chain variable fragment (scFv). Immune checkpoint inhibitors targeting PD-1 represent a major advance in treating several forms of cancer. The data showed that all three versions of the VV-PD-1 expression products displayed (i) a perfect biochemical integrity and folding, (ii) were fully functional, and (iii) had equivalent biological activity to the corresponding anti PD-1 reference mAb. Furthermore, the biodistribution profile obtained for VV-PD-1 demonstrated a higher concentration and prolonged action of the anti PD-1 in the tumor, resulting in an improved tumor/serum ratio.
…/…